SALIXIN A/S: Financial statements 2022
CVR: 33776748
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
SALIXIN A/S (CVR 33776748) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 496,370 and a net result of DKK 54,927 compared with DKK 6,344,740 the year before. That is a decrease of 94.5% compared with the year before. Equity in the 2022 report amounted to DKK 3,950,299. The solvency ratio was 40.3%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 496,370
- Profit/Loss
- DKK 54,927
- Equity
- DKK 3,950,299
- Total Assets
- DKK 9,809,953
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 496 t. | 55 t. | 4 mio. | 1 |
| 2021 | - | 9.1 mio. | 6.3 mio. | 3.9 mio. | 2 |
| 2020 | - | 70 t. | -746 t. | -2.4 mio. | 2 |
| 2019 | - | -5 t. | -889 t. | -1.7 mio. | 2 |
| 2018 | - | -235 t. | -974 t. | -814 t. | 2 |
Official annual report
Keep an eye on SALIXIN A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of December 21, 2022, A/S PSE 17 NR. 1056 has been appointed auditor of SALIXIN A/S.
SALIXIN A/S has published its annual report for 2021. Gross profit came to DKK 9,103,319, and the net result was DKK 6,344,740.
As of March 24, 2022, Michael Bundgaard has joined the board of directors of SALIXIN A/S.
As of March 24, 2022, Henrik Lyngsø Bach has joined the board of directors of SALIXIN A/S.
As of March 24, 2022, Andreas Ydesen has joined the board of directors of SALIXIN A/S.
As of March 24, 2022, Andreas Ydesen is registered as director of SALIXIN A/S.
As of March 24, 2022, Henrik Lyngsø Bach has stepped down as director of SALIXIN A/S.
As of March 23, 2022, Henrik Lyngsø Bach has left the board of directors of SALIXIN A/S.
As of March 23, 2022, Andreas Ydesen has left the board of directors of SALIXIN A/S.
About SALIXIN A/S
SALIXIN A/S is a Danish company of the type Aktieselskab based in Tylstrup, founded in 2011. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Allan Juul Bech. The board consists of Michael Bundgaard (chair), Allan Juul Bech and Louise Bech. The company is owned by Ny Vraa A/S. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK 169,447 and a net result of DKK 106,174 compared with DKK 1,051,659 the year before. Equity in the 2025 report amounted to DKK 124,343.